Heron Therapeutics | HRTX - Cash And Equivalent


Heron Therapeutics reported $43.07M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
ALKERMES USD 388.57M 227.88M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
ANI Pharmaceuticals USD 285.58M 22.98M Dec/2025
Anika Therapeutics USD 57.48M 509K Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Eisai JPY 301.65B 16.27B Sep/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Insmed USD 510.44M 175.68M Dec/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 158.54M 10.96M Dec/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Surmodics USD 36.11M 11.81M Sep/2024
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Veracyte USD 362.58M 47M Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025